HSC was comparable to oxytocin and superior to misoprostol in the prevention of uterine atony after c-section. Further uterotonics were needed for the treatment of 5 (6%) patients who were treated with HSC, 20 (22%) patients treated with misoprostol, and 11 (13%) patients treated with oxytocin. In the prevention of uterine atony, HSC was comparable with oxytocin (RR 0.41, 95% CI 0.14–1.25) and superior to misoprostol (RR 0.21, 95% CI 0.07–0.58). The gene discussed is OXT; the disease is Uterine Inertia.